title: Letter to the editor. Re: Cost-effectiveness analysis of disease modifying drugs (-interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients. Sánchez-de la Rosa R, Sabater E, Casado MA, Arroyo R. JME 2012;15(3):424–33.
authors.forename: Ángel Sanz
authors.initials: ÁS
authors.lastname: Granda
authors.forename: Laura García
authors.initials: LG
authors.lastname: Jurado
authors.forename: Carlos Polanco
authors.initials: CP
authors.lastname: Sánchez
mesh_terms: D000276:Adjuvants, Immunologic / Q000191:economics*; D000970:Antineoplastic Agents / Q000191:economics*; D006801:Humans; D007372:Interferons / Q000191:economics*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D010455:Peptides / Q000191:economics*
chemical_list: D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D010455:Peptides; D007372:Interferons